Huapont Life Sciences Co (002004) Fair Value & Analysis
Basic Materials · CN · Market cap 8.6B CNY
Fair value as of: Jul 21, 2026
From 24 valuation models · updated 20 days ago
Fair value updated Jul 21, 2026, revised from ¥7.55 to ¥5.16 (−31.7%) since Jun 25, 2026. Share price +8.0% over the past month.
A solid business, screening 16% undervalued on our models.
What matters now
- Our model range runs from ¥3.87 (bear) to ¥6.45 (bull), base ¥5.16. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 59/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range ¥3.56 – ¥8.20 · fair‑value band ¥3.87 – ¥6.45 · the ¥4.43 price screens below the ¥5.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Huapont Life Sciences Co (002004) currently trades at ¥4.43, while our model-based Fair Value estimate is ¥5.16, implying the stock looks roughly 16.5% undervalued today. The Quality Score stands at 59/100 (solid quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Huapont Life Sciences Co generated revenue of 11.5B CNY at a net margin of 5.9%. Revenue declined 0.1% year over year. It earns a return on equity of 5.3%. Net debt stands at 2.3B CNY. Fundamentals as of Jul 21, 2026
Our scenario range runs from ¥3.87 (bear case) to ¥6.45 (bull case); at ¥4.43, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 27% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -13% fair-value upside, at 16%, 002004 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (¥14.70) versus Asset-Based (¥3.46). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 46
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Huapont Life Sciences Co.,Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally. The company is involved in the production and sale of pharmaceutical preparations and raw materials.
Full company description
Huapont Life Sciences Co.,Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally. The company is involved in the production and sale of pharmaceutical preparations and raw materials. It also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and cardiovascular, as well as health management products. In addition, the company provides pesticide technical, intermediate and preparation products, and GLP registration technical services. Further, it engages in the research and development, production, and sales of fine chemical products and polymer materials, as well as provides tourism services and agent for the promotion of preparation products. The company was formerly known as Huapont-Nutrichem Co., Ltd. and changed its name to Huapont Life Sciences Co.,Ltd. in September 2015. Huapont Life Sciences Co.,Ltd. was founded in 1992 and is headquartered in Chongqing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Huapont Life Sciences Co reported revenue of ¥11.5B in FY2025 versus ¥12.4B in FY2021, a compound −1.9%/yr. Reported net income was ¥713M in FY2025, compounding +1.7%/yr from FY2021.
Watch 002004: get an alert when its fair value changes →
Peer Group
Agricultural Inputs · 179 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Agricultural Inputs median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Corteva, Inc CTVA | $86.07 | $27.81 | -68% |
| Nutrien Ltd NTR | C$94.23 | C$81.69 | -13% |
| Qinghai Salt Lake Industry Co 000792 | ¥24.93 | ¥21.26 | -15% |
| CF Industries Holdings CF | $119.19 | $161.00 | +35% |
| SABIC Agri-Nutrients Company 2020 | 122.90 SAR | 127.31 SAR | +4% |
| Yara International ASA YAR | kr 451.30 | kr 67.25 | -85% |
| Yunnan Yuntianhua Co 600096 | ¥30.17 | ¥42.12 | +40% |
| Asia-potash International Investment (Guangzhou)Co.,Ltd., 000893 | ¥42.59 | ¥38.01 | -11% |
| Coromandel International Limited COROMANDEL | ₹2,034 | ₹1,129 | -44% |
| UPL Limited UPL | ₹594.75 | ₹387.06 | -35% |
Compare Huapont Life Sciences Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Huapont Life Sciences Co (002004) overvalued or undervalued?
What is the fair value of 002004?
What is the quality score of 002004?
What is the revenue of Huapont Life Sciences Co (002004)?
What is the net profit margin of 002004?
Does Huapont Life Sciences Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Huapont Life Sciences Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.